

Pirh2 Antibody
Purified Mouse Monoclonal Antibody
Catalog # AO1358a

Specification

Pirh2 Antibody - Product Information

Application	WB, IHC, FC, IF
Primary Accession	O96PM5
Reactivity	Human, Rat
Host	Mouse
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	30kDa; 60kDa (homodimer) KDa

Description

Pirh 2 (P53 induced RING-H2 protein), also known as RCHY1, it forms dimers through its N- and C-terminus in cells. The Pirh2 has ubiquitin-protein ligase activity and it binds with p53 and promotes the ubiquitin-mediated proteosomal degradation of p53. The Pirh2 is oncogenic because loss of p53 function contributes directly to malignant tumor development. Pirh2 expression decreases the level of p53, and a decrease of endogenous Pirh2 expression increases p53 levels. Pirh2 is therefore considered, together with MDM2, to act as a negative regulator of p53 function.

Immunogen

Purified recombinant fragment of human Pirh2 expressed in E. Coli.

Formulation

Ascitic fluid containing 0.03% sodium azide.

Pirh2 Antibody - Additional Information

Gene ID 25898

Other Names

RING finger and CHY zinc finger domain-containing protein 1, 6.3.2.-, Androgen receptor N-terminal-interacting protein, CH-rich-interacting match with PLAG1, E3 ubiquitin-protein ligase Pirh2, RING finger protein 199, Zinc finger protein 363, p53-induced RING-H2 protein, hPirh2, RCHY1, ARNIP, CHIMP, PIRH2, RNF199, ZNF363

Dilution

WB~~1/500 - 1/2000
IHC~~1/200 - 1/1000
FC~~1/200 - 1/400
IF~~1/200 - 1/1000

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Pirh2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Pirh2 Antibody - Protein Information

Name RCHY1

Function

E3 ubiquitin-protein ligase that mediates ubiquitination of target proteins, including p53/TP53, TP73, HDAC1 and CDKN1B (PubMed: [16914734](http://www.uniprot.org/citations/16914734)), PubMed: [17721809](http://www.uniprot.org/citations/17721809), PubMed: [18006823](http://www.uniprot.org/citations/18006823), PubMed: [19043414](http://www.uniprot.org/citations/19043414), PubMed: [19483087](http://www.uniprot.org/citations/19483087), PubMed: [21994467](http://www.uniprot.org/citations/21994467)). Mediates ubiquitination and degradation of p53/TP53; preferentially acts on tetrameric p53/TP53 (PubMed: [19043414](http://www.uniprot.org/citations/19043414), PubMed: [19483087](http://www.uniprot.org/citations/19483087)). Catalyzes monoubiquitinates the translesion DNA polymerase POLH (PubMed: [21791603](http://www.uniprot.org/citations/21791603)). Involved in the ribosome-associated quality control (RQC) pathway, which mediates the extraction of incompletely synthesized nascent chains from stalled ribosomes: RCHY1 acts downstream of NEMF and recognizes CAT tails associated with stalled nascent chains, leading to their ubiquitination and degradation (PubMed: [33909987](http://www.uniprot.org/citations/33909987)).

Cellular Location


Nucleus. Nucleus speckle. Cytoplasm

Pirh2 Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Pirh2 Antibody - Images






Figure 1: Western blot analysis using Pirh2 mouse mAb against Hela (1), A549 (2), MCF-7 (3) and PC-12 (4) cell lysate.




Figure 2: Immunohistochemical analysis of paraffin-embedded human Tonsil tissues using anti-Pirh2 mouse mAb




Figure 3: Flow cytometric analysis of PC-12 cells using anti-Pirh2 mAb (blue) and negative control (red).




Figure 4: Immunofluorescence analysis of HeLa cells using Pirh2 mouse mAb (green). Red: Actin filaments have been labeled with Alexa Fluor-555 phalloidin.

Pirh2 Antibody - References

1. Biochem Biophys Res Commun. 2007 Dec 14;364(2):344-50.
2. J Natl Cancer Inst. 2004 Nov 17;96(22):1718-21.
3. Exp Cell Res. 2006 Oct 15;312(17):3370-8.
4. Cell. 2003 Mar 21;112(6):779-91.